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ABSTRACT
Sesamin is a major lignan in sesame, and its biological effects such as antioxidant effect, anti-carcinogenic effects, and
suppression of hypertension have been extensively studied by many researchers. However, its metabolic pathways and metabolic
enzymes in human bodies have not been identified. Recently we demonstrated that CYP2C9 was the most important cytochrome
P450 isoform in human liver. Next, we focused on metabolism of sesamin mono-catechol by cytochrome P450 or
UDP-glucuronosyltransferase (UGT). Further catecholization of sesamin mono-catechol by cytochrome P450 enhances its
anti-oxidant activity, whereas glucuronidation by UGT strongly reduces anti-oxidant activity. In human liver microsomes,
glucuronidation activity toward sesamin mono-catechol was much higher than the di-catecholization activity. In contrast, both
activities were similar in rat liver microsomes. These results suggest a large species-based difference between humans and rats in
sesamin metabolism. In vitro studies using 10 individual human liver microsomes suggested that UGT2B7 was responsible for
glucuronidation of sesamin mono-catechol in human liver. In addition, we observed a significant methylation activity toward
sesamin mono-catechol by catechol O-methyl transferase (COMT) in human liver cytosol. Based on these results, we concluded
that CYP2C9, UGT2B7, and COMT played essential roles in the metabolism of sesamin in human liver.
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INTRODUCTION
Sesamin is a major lignan in sesame, and its biological effects such as antioxidant, cholesterol- and
lipid-lowering, anticarcinogenic effects, and suppression
of hypertension have been extensively studied by many
researchers(1-7). Among them, antioxidant effects appear
to be attributed to its metabolites, because sesamin itself
has little antioxidative properties.
Sesamin was converted to its mono- and dicatechol
forms by P450s in rat liver to show high antioxidative
activity(1). In addition, recent studies suggested that sesamin monocatechol had the ability to induce enhancement
of endothelium-dependent vasorelaxation(8) and neuronal
differentiation(9). Thus, the conversion of sesamin to its
mono- or dicatechol form is considered to be an important
reaction in the production of antioxidants and other bioactive compounds. On the other hand, very little is known
about the plasma concentrations of sesamin mono- and
dicatechols in humans. Recently, Moazzami et al.(10) suggested the presence of glucuronide of sesamin monocatechol in human urine, but other metabolites such as dicatechol were not detected. Our recent studies demonstrated the conversion of sesamin to its monocatechol by
P450s in human liver microsomes(11). However, the dicatechol form was not detected. Our results are consistent

with those of Moazzami et al.(10) and suggest a species-based difference in sesamin metabolism by P450
between humans and rats. To understand the biological
significance of the sesamin metabolites, it is essential to
reveal what controls the ratio of conversion of sesamin to
its mono- or dicatechol or glucuronide forms. In addition,
from the viewpoint of drug-sesamin interaction, it is important to identify the P450 and UGT isoforms that are
responsible for sesamin metabolism. Our previous study
clearly demonstrated that the most essential P450 isoform
for sesamin metabolism is CYP2C9 and secondly
CYP1A2 in human liver. We also found a weak mechanism-based inhibiton (MBI) of CYP2C9 by sesamin(11) as
well as other MDP compounds.
To reveal overall metabolic pathways of sesamin in
humans, we focused on the metabolism of sesamin that
occurs after its monocatecholization. First, we identified
the
UGT
isoform
responsible
for
sesamin
glucuronidation, and then we examined methylation of
sesamin monocatechol by catechol O-methyl transferase
(COMT). Finally we describe a species-based difference
between humans and rats in sesamin metabolism(12).

MATERIALS AND METHODS
I. Apparatus and Conditions
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HPLC conditions are described below: column,
YMC-pack ODS-AM (4.6 × 300 mm) (YMC Co., Tokyo,
Japan); UV detection, 280 nm; flow late, 1.0 mL/min;
column temperature, 40ºC; linear gradients of 10 - 90%
methanol
aqueous
solution
containing
0.05%
trifluoroacetic acid (TFA) in 30 min, and 90 - 100% containing 0.05% TFA in 5 min for metabolites of sesamin
and sesamin monocatechol. 3’-Azido-3’- deoxythymidine
(AZT) metabolites by UGT were analyzed under the following conditions: column, YMC-pack ODS-AM (4.6 ×
300 mm) (YMC Co., Tokyo, Japan); UV detection, 267
nm; flow late, 1.0 mL/min; column temperature, 40ºC;
linear gradients of 10 - 65% methanol aqueous solution
containing 0.05% trifluoroacetic acid (TFA) in 20 min.
II. Materials and Reagents
Sesamin was purchased from Sigma-Aldrich (St.
Louis, MO). NADPH and NADH were purchased from
Oriental Yeast Co., Ltd. (Tokyo, Japan). UDP-GlcUA,
Escherichia coli -glucuronidase and S-adenosyl methionine (SAM) were purchased from Sigma-Aldrich (St.
Louis, MO). Human single donor liver microsomes
(HG43, HH47, HH18, HH74, HH77, HG95, HH715,
HH581, HG3, and HH741), a 50 donor human liver microsomes pool, human liver cytosol pool, male Sprague-Dawley male rat liver microsomes and cytosol, and
recombinant human UGTs (UGT1A1, 1A3, 1A4, 1A6,
1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, 2B17) expressed
in baculovirus-infected insect cells were purchased from
BD Gentest (Woburn, MA). All other chemicals were
purchased from standard commercial sources of the
highest quality available.

The kinetic studies for P450-dependent oxidation,
UGT-dependent glucuronidation, and COMT-dependent
methylation were performed using each of the
microsomal and cytosolic fractions. The kinetic
parameters, Km and Vmax, were calculated by the nonlinear
regression analysis using KaleidaGraph (Synergy
Software, Reading, PA). The equation was applied for
Michaelis-Menten kinetics.

RESULTS AND DISCUSSION
I. Metabolism of Sesamin in Hhuman Liver
We demonstrated the successive metabolism of sesamin in human liver microsomes as shown in Figure 1 (12).
Sesamin was first metabolized to monocatechol metabolite in human liver microsomes in the presence of
NADPH. When the monocatechol was used as a substrate,
dicatechol (SC-2) was detected in the presence of
NADPH. On the other hand, a glucuronide of SC-1
(SC-1-GlcUA) was detected in the presence of
UDP-glucuronic acid in human liver microsomes, and
two methylated metabolites of SC-1 (SC-1m) were detected in the presence of SAM in human liver cytosol(12).
Only one glucuronide was detected in human liver microsomes, while both glucuronide isomers were detected
in rat liver microsomes.
Figure 1. Metabolic pathways of sesamin in human liver.

III. Measurement of CYP, UGT, and COMT Activities
In the dicatechol formation by P450, the reaction
mixture containing 0.5 mg protein/mL of the liver microsomes, 1 - 50 M sesamin monocatechol, 1 mM NADPH
in 100 mM potassium phosphate buffer (pH 7.4) was incubated for 10 - 30 min at 37ºC and the metabolite was
analyzed by HPLC.
In UGT-dependent glucuronidation of sesamin
monocatechol, the reaction mixture containing 0.5 mg
protein/ml of the liver microsomes, 1 - 50 M sesamin
monocatechol, 2 mM UDP-GlcUA, 1mM MgCl2 in 100
mM potassium phosphate buffer (pH 7.4) was incubated
for 15 - 30 min at 37ºC, and the metabolite was analyzed
by HPLC. The aliquot of the reaction mixture was further
incubated for 60 min at 37ºC in the presence of 0.1
mg/mL -glucuronidase in 20 mM potassium phosphate
buffer (pH 7.4) to confirm that the metabolite was the
glucuronide.
In COMT-dependent methylation, the reaction
mixture containing 0.5 mg protein/mL of the liver
cytosol, 1 - 50 M sesamin monocatechol, 200 M SAM,
2 mM MgCl2, 1 mM dithiothreitol, in 100 mM potassium
phosphate buffer (pH 7.4) was incubated for 5 - 20 min at
37ºC, and then the metabolites were analyzed by HPLC.
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II. Identification of CYP and UGT Isoforms Responsible
for Sesamin Metabolism
From the viewpoint of the safety taking of sesamin
with the therapeutic drugs, it is important to identify the
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P450 and UGT isoforms which are responsible for sesamin metabolism.
Our previous studies revealed that the oxidation reaction of sesamin was catalyzed by many of human
drug-metabolizing P450s (CYP1A1, 1A2, 2A6, 2B6, 2C8,
2C9, 2C18, 2C19, 2D6, and 3A4). Of these P450s,
CYP2C9 was the enzyme responsible for metabolism of
sesamin in human liver microsomes, and the secondary
most important P450 was CYP1A2, whereas contribution
of CYP1A2 was small(11). Furthermore, we examined the
metabolism of sesamin monocatechol (SC-1) by recombinant human UGTs expressed in baculovirus-infected
insect cells. Among the 12 UGT isoforms (UGT1A1, 1A3,
1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and
2B17), UGT2B7 and UGT2B17 showed a glucuronidation activity towards SC-1. The Vmax/Km of UGT2B7 was
approximately 3 times higher than that of UGT2B17. In
addition, the expression level of UGT2B7 is significantly
higher than UGT2B17 in human liver. These results suggest that UGT2B7 is the most important UGT isoform in
the sesamin metabolism in human liver.
It is noted that inter-individual difference among 10
human liver microsomes is approximately 2-fold in both
oxidation of sesamin by P450 and glucuronidation of
SC-1 by UGT. These findings suggest a small inter-individual difference in sesamin metabolism.
III. Mechanism-Based Inhibition of CYP2C9 by Sesamin
Because sesamin is the substrate for most of the
drug-metabolizing P450 isoforms as described above, any
apparent competitive inhibition would be observed in the
activities of those P450 isoforms. We examined the inhibitory effect of sesamin on CYP2C9-, 1A2-, and
3A4-dependent activities. Competitive inhibition by
sesamin was observed in all three isoforms. The apparent
Ki values of sesamin on CYP2C9, 1A2, and
3A4–dependent activities were 24, 75, and 4.2 μM, respectively. Thus, sesamin was found to be a potent inhibitor of CYP3A4.
From the viewpoint of the interaction with therapeutic drugs, we have to be more careful about the irreversible
inhibition,
which
is
called
mechanismbased-inhibition (MBI), because the inhibitory effects are
continued even after disappearance of inhibitory substance. Some reports have been published about MBI of
P450s by methylenedioxyphenyl (MDP) compounds.
There is a high possibility of the MBI of P450s by sesamin, because sesamin has two MDP groups. We examined the sesamin-dependent MBI of P450s, and demonstrated the MBI of CYP2C9 with the kinetic parameters
kinact; 0.13 /min, Ki app; 22 μM, although sesamin showed
no MBI of CYP1A2. The kinact/Ki app value of sesamin
(0.0059 /min/μM) was much lower than those of other
methylenedioxyphenyl lignans(13). However, this value is
not so different from those of the well-known MBI inhibitors of CYP3A4 in grapefruit components such as
bergamottin (0.002 - 0.071 /min/μM)(14,15).
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Figure 2. Comparison of metabolism of sesamin between human
liver and rat liver. Thickness of arrows roughly represents the
strength of the activity.

IV. Spiecies-Based Differences in the Metabolism of
Sesamin Between Humans and Rats
Recently, we determined the kinetic parameters of
the first and second reactions of sesamin metabolism using microsomal fraction and cytosolic fraction prepared
from human liver or rat liver, and demonstrated remarkable species-based differences between humans and
rats(12). The Vmax/Km values of P450-dependent catecholization and UGT-dependent glucuronidation activities
were quite different between humans and rats, whereas
COMT-dependent methylation activity was at a similar
level as shown in Figure 2. In rats, catecholisation by
P450 was predominant over glucuronidation by UGT.
These results appear to be consistent with the findings
that monocatechol (SC-1) and dicatechol (SC-2) are the
major metabolites in in vivo study using rats(8). On the
other hand, glucuronidation by UGT was predominant
over catecholization by P450 in humans. Therefore, in the
human body, catechol metabolites (SC-1 and SC-2)
would exist at a low concentration, while the glucuronidation metabolite (SC-1-GlcUA) would be the major metabolite. Because glucuronide (SC-1-GlcUA) appears to have no bioactivity, it is possible that the biological activities of the catechol metabolites might not be
expected as much in humans. However, Kawai et al.(16)
proposed a novel mechanism for the function of quercetin
in humans. Quercetin is mainly converted to its glucuronide form at the 3-position (Q3GA) by UGTs in the
liver. Q3GA in the plasma could be taken up by macrophage cells probably by some transporters in the plasma
membrane, and converted into its active aglycone form by
-glucuronidase. This finding could explain why
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quercetin is effective to atherosclerosis in spite of the
absence of quercetin aglycone in the serum. A similar
mechanism might be applied to sesamin, because
-glucuronidase is expressed in most mammalian tissues.

8.

CONCLUSIONS
We examined metabolism of sesamin by human
drug-metabolizing enzymes, and revealed that CYP2C9,
UGT2B7, and COMT were the most important enzymes
in the metabolism of sesamin in the human liver. In addition, we compared sesamin metabolism between humans
and rats and revealed the significant species-based difference. Inhibition studies clearly demonstrated the MBI
of CYP2C9 by sesamin. Although we cannot conclude
how serious the MBI is by sesamin at the present time, in
vivo studies should be required to evaluate the interaction
between sesamin and the therapeutic drugs metabolized
by CYP2C9 such as diclophenac, phenytoin, indomethacin, and S-warfarin.
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